Pharmaceutical and Biomedical

science1The breathtaking pace of scientific discovery has fueled an explosion of new data on biologic modulators and disease mechanisms, as well as new approaches for understanding and replicating biological processes at a molecular level. At the same time, however, translating these discoveries into viable treatments for clinical practice remains a daunting task that is fraught with failure, a process that has become even more difficult as concerns over safety have lengthened the timelines and raised the costs of clinical development. Stricter regulatory regimes and pressures on payers to constrain costs have placed a premium on clearly differentiating new products to highlight the value they deliver over existing products. To position themselves for success, corporations must understand the changing market dynamics in the US and other established markets while tapping into the enormous growth opportunities in emerging markets. More than ever before, the dimensions of competition are increasingly defined by the ability to integrate outside resources with internal, cross-disciplinary expertise, leveraging the best science and partnering with a variety of private and public organizations to rapidly and efficiently address unmet medical needs.

MSA publishes widely-distributed research reports as well as weekly and monthly subscription-based periodicals to provide pharmaceutical and life sciences companies with relevant and timely information and analysis about policy and market developments. In addition to providing customized research and consulting services, MSA works with Japan’s top life sciences companies to identify market opportunities and position them in the market.